JP2009538359A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538359A5
JP2009538359A5 JP2009513381A JP2009513381A JP2009538359A5 JP 2009538359 A5 JP2009538359 A5 JP 2009538359A5 JP 2009513381 A JP2009513381 A JP 2009513381A JP 2009513381 A JP2009513381 A JP 2009513381A JP 2009538359 A5 JP2009538359 A5 JP 2009538359A5
Authority
JP
Japan
Prior art keywords
pain
enantiomer
compound
group
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009513381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538359A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/069480 external-priority patent/WO2007140189A2/en
Publication of JP2009538359A publication Critical patent/JP2009538359A/ja
Publication of JP2009538359A5 publication Critical patent/JP2009538359A5/ja
Pending legal-status Critical Current

Links

JP2009513381A 2006-05-26 2007-05-22 置換カルボン酸化合物の製造および利用 Pending JP2009538359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80910706P 2006-05-26 2006-05-26
US84136706P 2006-08-30 2006-08-30
PCT/US2007/069480 WO2007140189A2 (en) 2006-05-26 2007-05-22 Preparation and utility of substituted carboxylic acid compounds

Publications (2)

Publication Number Publication Date
JP2009538359A JP2009538359A (ja) 2009-11-05
JP2009538359A5 true JP2009538359A5 (enExample) 2010-07-08

Family

ID=38779326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009513381A Pending JP2009538359A (ja) 2006-05-26 2007-05-22 置換カルボン酸化合物の製造および利用

Country Status (7)

Country Link
US (1) US20070276042A1 (enExample)
EP (1) EP2020849A2 (enExample)
JP (1) JP2009538359A (enExample)
AU (1) AU2007267612A1 (enExample)
BR (1) BRPI0711228A2 (enExample)
CA (1) CA2653262A1 (enExample)
WO (1) WO2007140189A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20022394A1 (it) * 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
CN102149280B (zh) 2008-07-15 2017-05-24 泰拉科斯有限公司 氘化苄基苯衍生物及其使用方法
CN102020521A (zh) * 2009-09-10 2011-04-20 陈松源 氘代中药单体的制备方法和应用
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
JP6191325B2 (ja) * 2012-08-10 2017-09-06 和光純薬工業株式会社 芳香族化合物の重水素化方法
CN102795991B (zh) * 2012-08-25 2014-07-23 神威药业集团有限公司 2-戊酰基-1,5-环己二烯-1-羧酸及其合成方法和应用
FR2997856B1 (fr) * 2012-11-14 2015-04-24 Pf Medicament Pastille medicamenteuse a base d'ibuprofene sodique dihydrate
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
WO2017070448A1 (en) * 2015-10-22 2017-04-27 The Trustees Of The University Of Pennsylvania 2-beta-naphthyl-acetic acid analogs as akr1c3 inhibitors and methods of using same
US11731947B2 (en) 2019-04-10 2023-08-22 University Of Notre Dame Du Lac Deuterated antimicrobial compounds
EP4452244A4 (en) * 2021-12-21 2026-02-18 Biojiva Llc ANTI-INFLAMMATORY METHODS INVOLVING SITE-SPECIFIC COMPOSITIONS COMPRISING ISOTOPICALLY MODIFIED FATTY ACIDS
CN114933516B (zh) * 2022-06-17 2024-01-30 句容宁武新材料股份有限公司 一种在离子液体介质中合成氘代化合物的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567183A (en) * 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US5093086A (en) * 1988-12-23 1992-03-03 Gte Products Corporation Packed bed reactor for photochemical 196 Hg isotope separation
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JP3985874B2 (ja) * 1994-11-11 2007-10-03 クラシエ製薬株式会社 感冒治療薬
US6348216B1 (en) * 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US6342530B1 (en) * 2000-11-14 2002-01-29 Farmacon-Il, Llc Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt
US6344479B1 (en) * 2001-03-20 2002-02-05 Farmacon-Il, Llc Method of preventing retinopathy of prematurity in a neonate
US6727286B2 (en) * 2001-11-02 2004-04-27 Cumberland Pharmaceuticals Inc. Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
DE10162120A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Dihydrofuranone sowie diese Verbindungen enthaltende Arzneimittel
DE10224888A1 (de) * 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
WO2003104166A1 (ja) * 2002-06-06 2003-12-18 和光純薬工業株式会社 不活性メチレンの重水素化方法
RU2331649C2 (ru) * 2002-06-20 2008-08-20 Ай-Си Ви-И-Си Лимитед Серосодержащие фосфолипидные производные, содержащая их фармацевтическая композиция, их применение для лечения заболеваний и способ их получения
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1575566B1 (en) * 2002-12-26 2012-02-22 Pozen, Inc. Multilayer dosage forms containing naproxen and triptans
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US20090062364A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched celecoxib
US20090076150A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched bromfenac
US20090076087A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched etoricoxib
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
US20090082450A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched diclofenac

Similar Documents

Publication Publication Date Title
JP2009538359A5 (enExample)
JP2012524085A5 (enExample)
JP2009511481A5 (enExample)
JP2010507585A5 (enExample)
JP2012503010A5 (enExample)
JP2009539863A5 (enExample)
AU2008265595B2 (en) Substituted N-Aryl pyridinones as fibrotic inhibitors
ES2693948T3 (es) Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
BRPI0809843A2 (pt) "composto, composição farmacêutica e uso de um composto"
US9526711B2 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
JP2009538359A (ja) 置換カルボン酸化合物の製造および利用
CA2981743A1 (en) Deuterium-substituted oxadiazoles
CA2936823A1 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2008141033A1 (en) Substituted naphthalenes
US20100291151A1 (en) 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
CA2631581A1 (en) Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
JP2016529228A5 (enExample)
JP2010512343A5 (enExample)
US20100075950A1 (en) Phenylpropanone modulators of dopamine receptor
US20090247628A1 (en) Substituted phenylcyclohexylglycolates
US20190381028A1 (en) Pharmaceutical composition for the treatment of parkinson's disease
JP2018507210A5 (enExample)
RU2024129873A (ru) Дейтерированные аналоги пиррольных ингибиторов erk, их синтез и промежуточные соединения
CN101511180A (zh) 取代的羧酸化合物的制备及应用
JPWO2020198529A5 (enExample)